Devonian Health Group Inc. (CVE:GSD – Get Free Report) shares traded down 23.5% on Saturday . The company traded as low as C$0.09 and last traded at C$0.13. 119,000 shares changed hands during trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Trading Down 23.5%
The firm has a market cap of C$19.27 million, a P/E ratio of -4.64 and a beta of 0.67. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36. The firm’s 50-day simple moving average is C$0.16 and its 200 day simple moving average is C$0.17.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Read More
- Five stocks we like better than Devonian Health Group
- How to buy stock: A step-by-step guide for beginners
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- How to Invest in Insurance Companies: A Guide
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- What is a Microcap Stock? Everything You Need to Know
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
